Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Richard Champlin
Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study
Dear Editor, Salvage or delayed autologous stem cell transplantation (ASCT) has historically been an important treatment option for relapsed/refractory multiple myeloma (RRMM). However, its role has been challenged in recent years with the emergence of highly active T-cell–redirecting therapies, including bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy [1].
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage
Abstract The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with B-cell–directed immunotherapies remains controversial. We analyzed 172 adults treated in first salvage with blinatumomab and/or inotuzumab ozogamicin (InO)–based regimens to determine prognostic factors and benefit from allo-HSCT after achieving remission.
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy
Comparative data between haploidentical and 7/8 mismatched unrelated donor (MMUD) hematopoietic stem cell transplant (HCT) in the post-transplantation cyclophosphamide (PTCy) era remain limited, particularly when accounting for contemporary, high-resolution Human Leucocyte Antigen (HLA) features such as B-leader matching, DPB1 T-cell epitope (TCE) groups, and peptide-binding motif (PBM) classifications [1,2,3,4].
D-VRD induction and autologous transplant in patients ≥70 years
|
Dear Editor, The addition of daratumumab to triplet induction regimens has significantly improved depth of response and progression-free survival (PFS) in newly diagnosed multiple myeloma (MM), as demonstrated in the GRIFFIN and PERSEUS trials, both of which evaluated daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRD) induction followed by autologous hematopoietic cell transplantation (autoHCT) [1, 2].
By Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Mark Tanner, Qaiser Bashir, Samer Srour, Neeraj K. Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra M. Aljawai, Asad Haider, Hans C. Lee, Partow Kebriaei, Sheeba K. Thomas, Robert Orlowski, Richard Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Muhammad Bilal Islam
|
Nature
Verified
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes
|
Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT.
By Alexandre Bazinet, Alex Bataller, Kelly S. Chien, Koji Sasaki, Guillermo Montalban-Bravo, Danielle Hammond, Ian Bouligny, Mahesh Swaminathan, Wei Ying Jen, Eitan Kugler, Rashmi Kanagal-Shamanna, Tapan M Kadia, Gautam Borthakur, Courtney DiNardo, Nicholas Short, Naveen Pemmaraju, Elias Jabbour, Farhad Ravandi, Samuel Urrutia, Georgina Gener-Ricos, Robert Briski, Juan José Rodríguez-Sevilla, Ziyi Li, Richard Champlin, Elizabeth J. Shpall, Amin M. Alousi, Betül Oran, Jeremy Ramdial, Amanda Olson, Sherry Pierce, Julianne Chen, Hagop Kantarjian, Guillermo Garcia-Manero, Uday Popat, Julie Braish
|
Nature
Verified
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide | Leukemia
Abstract Disease progression, graft-versus-host disease (GVHD), and non-relapse mortality (NRM) are the main causes of failure after allogeneic hematopoietic cell transplantation (SCT) for myeloid neoplasms. T-cell epitope–based models classify HLA-DPB1 mismatches by permissiveness and have been associated with differential risks of GVHD, relapse, and NRM.
Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes - npj Digital Medicine
Abstract We developed a novel, explainable artificial intelligence (AI)-driven prognostic model using a contemporary single-centre cohort of 668 patients undergoing haploidentical hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide (PTCy) prophylaxis (2015–2024) to define the hierarchy of prognostic factors for overall survival.
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis | Leukemia
Abstract The prevailing fixed-hierarchy approach to donor selection for allogeneic hematopoietic cell transplantation (HCT) fails to capture critical interactions between donor age and type. We addressed this by analyzing 1713 adult recipients of matched related (MRD), matched unrelated (MUD), or haploidentical donors, receiving post-transplantation cyclophosphamide, using both regularized-Cox and XGBoost machine learning models.
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma - Bone Marrow Transplantation
Abstract Autologous hematopoietic cell transplantation (autoHCT) remains a therapeutic option for multiple myeloma (MM) at relapse. We retrospectively analyzed 650 patients who underwent delayed (n = 335) or salvage (n = 315) autoHCT at a single center from 2006–2023. Median age was 61.4 years; 22% were Black, and 21% had high-risk cytogenetics. Forty-nine percent received >3 prior therapy lines, and 33% were lenalidomide-refractory. Non-relapse mortality was 3% at day 100 and 4% at 1 year.
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease - Bone Marrow Transplantation
Abstract Minnesota acute graft versus host disease (AGVHD) risk score is a validated tool to stratify newly-diagnosed patients into standard-risk (SR) and high-risk (HR) groups with ~85% having SR AGVHD. We aimed to identify factors for further risk-stratification within Minnesota SR patients. A single-center, retrospective analysis of consecutive patients between 1/2010 and 12/2014 was performed.
"Early and Rapid Development of Bronchiolitis Obliterans Syndrome after" by Jacqueline S Dickey, Burton F Dickey et al.
Home > UTHealth > GSBS > Journal Articles > 599 Respiratory Medicine Case Reports Bronchiolitis obliterans syndrome, Hematopoietic cell transplantation, Handheld spirometry, Screening DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Medical Specialties Commons, Respiratory Tract Diseases Commons COinS
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis - Leukemia
As donor age is a significant predictor of hematopoietic cell transplantation (HCT) outcomes [1, 2], a common clinical dilemma for patients with both an HLA-matched related and an unrelated donor is whether to select a “younger” matched unrelated donor (MUD) or an “older” matched sibling donor (MSD). A few prior studies compared HCT outcomes between these two donor types, taking donor age into consideration.
Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML
CONFLICT OF INTEREST STATEMENT DAL is on the scientific advisory board and receives consulting fees from Avidicure B.V.; receives consulting fees from Catamaran Bio; receives consulting, licensing, and royalty fees from Kiadis Pharma (a Sanofi Company); and has intellectual property interests related to NK cell therapy. Supporting Information Filename Description ajh27281-sup-0001-supinfo.pdfPDF document, 963.7 KB Data S1. Supporting information. REFERENCES 1, , , .
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis - Bone Marrow Transplantation
Toxoplasma gondii is an opportunistic infection in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients and could lead to life-threatening complications such as pneumonia, meningoencephalitis, or disseminated disease with mortality rate of up to 60% [1, 2]. Toxoplasmosis usually occurs secondary to reactivation of latent Toxoplasma infection rather than through new encounter [3, 4].
Hematopoietic cell transplantation can be safely performed after COVID-19 - Bone Marrow Transplantation
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 269,00 € per year only 22,42 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout References Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis.
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement - Bone Marrow Transplantation
Abstract Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a study, we evaluated the safety and efficacy of ALXN1007, a monoclonal antibody against C5a, in patients with newly diagnosed LGI acute GVHD receiving concomitant corticosteroid. Twenty-five patients were enrolled; one was excluded from the efficacy analysis based upon negative biopsy.
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant - Bone Marrow Transplantation
Abstract Dual expression of MYC and BCL2 proteins (double-expressor lymphoma [DEL]) as well as cell of origin (COO) are important prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) after conventional chemotherapy. We studied the prognostic impact of DEL and COO in patients with relapsed DLBCL treated with autologous stem cell transplant (ASCT). Three-hundred and three patients with stored tissue samples were identified.
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation
Abstract Clonal hematopoiesis (CH) is associated with older age and an increased risk of myeloid malignancies and cardiovascular complications. We analyzed donor DNA samples in patients with AML/MDS who underwent first allogeneic stem cell transplant (SCT) to investigate the association between donor CH and transplant outcomes. We performed targeted deep sequencing of 300 genes on donor blood samples and identified CH with the minimum variant allele frequency of 2%.
Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma
Outcome of patients with standard-risk (SR) multiple myeloma (MM) has improved; however, subsets of patients do worse than expected. We sought to identify the factors associated with inferior outcome. We evaluated 51 patients with SR MM that received upfront autologous hematopoietic stem cell transplantation (auto-HCT) after induction and had a progression-free survival (PFS) of ?18 months. The median age of patients was 61 yr.
Epstein-Barr virus status affects GVHD risk after HSCT
We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). ... Donor Epstein–Barr virus donor and recipient status significantly influenced risk for acute and chronic graft-versus-host disease among patients with leukemia undergoing allogeneic hematopoietic stem cell transplantation, according to study results from the European Society for Blood and Marrow Transplantation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Richard
Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack